Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elzasonan and Sertraline in MDD
NCT00275197Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of elzasonan in major depressive disorder (MDD) (3 arms), sponsored by Pfizer. Primary endpoint: Montgomery-Asberg Depression Rating Scale remission rates at 8 weeks. Started Dec 2005; status: completed.
02
Drugs
elzasonan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00275197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275197.